BioCentury | Oct 6, 2018
Finance

Seeking validation

...of origin PDUFA data 11/26/18 Mayne Pharma Group Ltd. (ASX:MYX) / HedgePath Pharmaceuticals Inc. (OTCQX:HPPI) SUBA-Itraconazole...
BioCentury | Aug 8, 2016
Clinical News

SUBA-Itraconazole: Interim Phase IIb data

...oral SUBA-Itraconazole for >=16 weeks reduced target tumor burden by >30% in 62% of patients. SUBA-Itraconazole...
...lesions showed a >30% reduction. SUBA-Itraconazole was well tolerated. HedgePath has exclusive, U.S. rights to SUBA-Itraconazole...
...Fla. Mayne Pharma Group Ltd. (ASX:MYX), Melbourne, Australia Product: SUBA-Itraconazole ( Lonzanoc , SUBA Itraconazole , Subacap...
BioCentury | Sep 7, 2015
Clinical News

SUBA-Itraconazole: Phase IIb started

...HedgePath began the open-label, U.S. Phase IIb SCORING trial to evaluate 100 mg oral SUBA-Itraconazole twice...
...Fla. Mayne Pharma Group Ltd. (ASX:MYX), Melbourne, Australia Product: SUBA-Itraconazole ( Lonzanoc , SUBA Itraconazole , Subacap...
BioCentury | Mar 8, 2010
Clinical News

SUBA-Itraconazole: Pivotal trial data

...Preliminary data from a U.K. pivotal pharmacokinetic study showed that a half-dose of SUBA-Itraconazole was bioequivalent...
...was bioequivalent to Sporanox itraconazole from Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.). Halcygen acquired SUBA-Itraconazole...
...the compound outside of Australia and New Zealand. HalcyGen Pharmaceuticals Ltd. (ASX:HGN), Melbourne, Australia Product: SUBA-Itraconazole...
BioCentury | Oct 5, 2009
Company News

HalcyGen, Hospira deal

...in cash, plus earn outs over six years. The deal gives HalcyGen full control over SUBA-Itraconazole...
BioCentury | Oct 13, 2008
Clinical News

Subazole: Pivotal trial data

...A pivotal study showed that SUBA-Itraconazole produced comparable pharmacokinetics to Sporanox itraconazole from Johnson & Johnson...
...itraconazole from Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.). Halcygen has exclusive worldwide rights to SUBA-Itraconazole...
...HalcyGen Pharmaceuticals Ltd. (ASX:HGN), Melbourne, Australia Hospira Inc. (NYSE:HSP), Lake Forest, Ill. Product: Subazole (formerly SUBA-Itraconazole...
BioCentury | Jun 23, 2008
Clinical News

Subazole: Pivotal trial started

...Halcygen began a U.S. pivotal pharmacokinetic study to evaluate oral SUBA-Itraconazole and Sporanox itraconazole from Johnson...
...New Brunswick, N.J.). Halcygen has exclusive worldwide rights outside of Australia and New Zealand for SUBA-Itraconazole...
...HalcyGen Pharmaceuticals Ltd. (ASX:HGN), Melbourne, Australia Hospira Inc. (NYSE:HSP), Lake Forest, Ill. Product: Subazole (formerly SUBA-Itraconazole...
BioCentury | Jun 16, 2008
Clinical News

HalcyGen, Hospira preclinical data

...Itraconazole, the active ingredient in Subazole, inhibited proliferation of endothelial cells involved in tumor-angiogenesis and tumor...
...growth in vitro. HalcyGen has exclusive worldwide rights outside of Australia and New Zealand to Subazole...
...HalcyGen Pharmaceuticals Ltd. (ASX:HGN), Melbourne, Australia Hospira Inc. (NYSE:HSP), Lake Forest, Ill. Product: Subazole (formerly SUBA-Itraconazole...
BioCentury | Dec 3, 2007
Clinical News

Subazole: Phase III start

...HGN will begin a U.S. Phase III trial to compare Subazole vs. Sporanox itraconazole capsules from...
...New Brunswick, N.J.). HGN has exclusive worldwide rights outside of Australia and New Zealand for Subazole...
...HalcyGen Pharmaceuticals Ltd. (ASX:HGN), Melbourne, Australia Hospira Inc. (HSP), Lake Forest, Ill. Product: Subazole (formerly SUBA-Itraconazole...
BioCentury | Aug 13, 2007
Clinical News

SUBA-Itraconazole: Phase II started

...HGN began an open-label Phase II in 12 patients. HGN has exclusive rights to SUBA-itraconazole outside...
...this year. HalcyGen Pharmaceuticals Ltd. (ASX:HGN), Melbourne, Australia Hospira Inc. (HSP), Lake Forest, Ill. Product: SUBA-Itraconazole...
Items per page:
1 - 10 of 13